Cyclerion Updates Corporate Progress

– Closed enrollment for olinciguat Phase 2 STRONG SCD study for sickle cell disease; topline data readout expected Q3 2020 –

      – Closed enrollment for IW-6463 translational pharmacology clinical study; topline data readout expected mid-year 2020 –

– Company continues discussions to out-license praliciguat –

CAMBRIDGE, Mass., April 10, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced that it recently closed enrollment for both of its ongoing clinical studies.  The Company also provided additional corporate updates.

“We are looking forward to a catalyst-rich period in the coming months with top line results from both our translational pharmacology study for IW-6463, our brain-penetrant sGC stimulator designed to treat neurodegenerative diseases, and our olinciguat Phase 2 study for sickle cell disease. We also continue discussions on the out-licensing of praliciguat, a potential best-in-class therapeutic candidate for cardio-metabolic diseases. Recent published outcomes data from other groups provide compelling new support for the use of the sGC stimulator class in treating cardiometabolic diseases”, said Peter Hecht, Ph.D., Chief Executive Officer of Cyclerion.

COVID-19

Cyclerion is executing against its previously communicated 2020 corporate priorities, advancing its ongoing olinciguat and IW-6463 clinical programs and out-licensing praliciguat.  The company is closely monitoring and adjusting its operations but the pandemic could affect these activities in ways that are difficult to precisely judge at this time.  The Company cannot give any assurances as to the potential impact of the pandemic on its operations, clinical trials, corporate development discussions and other activities.  Cyclerion is working closely with its clinical trial sites and investigators to deliver its ongoing and planned trials in a manner consistent with the safety of study participants and healthcare professionals. Cyclerion does not anticipate any drug product disruption for its clinical trials and is taking steps to mitigate any disruptions of clinical supply materials to trial participants.